4ml tirzepatide 249.00 | --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1) Most Successful Weight Loss Program. Weighing benefits, risks of GLP-1

The company launched its first partnered GLP-1, Liraglutide, marking its entry into this high-potential market segment

SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism

Based on Phase 2 trial data, the most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and decreased appetite

Studies show GLP-1 users report 1525% lower daily water consumption than baseline, increasing dehydration risk and raising serum creatinine levels

The semaglutide group significantly reduced their number of heavy drinking days

Based on target consumer, GLP-1 Users for Weight Management represent approximately 31.80% share in 2026, driven by the high adoption of GLP-1 agonists specifically for weight loss and the corresponding need for protein, hydration, and micronutrient support